2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Evening Seminar

[ES23] Evening Seminar 23　Brigatinib for ALK-positive non-small cell lung cancer (NSCLC) in the first-line setting: A Korean experience
【SI】

Fri. Feb 18, 2022 6:40 PM - 7:30 PM Room 2 and 3 (Annex 1 and 2, 1F, Kyoto International Conference Center)

Chair：Hidetoshi Hayashi（Kindai University Faculty of Medicine, Department of Medical Oncology）

Sponsored by Takeda Pharmaceutical Company Limited

[ES23-1] Brigatinib for ALK-positive non-small cell lung cancer (NSCLC) in the first-line setting: A Korean experience

○Hye Ryun Kim (Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea)